The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Open accessThe DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.
Abstract
The nongenetic mechanisms required to control tumor phenotypic plasticity and shape drug‐resistance remain unclear. We show here that the Aryl hydrocarbon Receptor (AhR) transcription factor directly regulates the gene expression program associated with the acquisition of resistance to BRAF inhibitor (BRAFi) in melanoma. In addition, we show in melanoma cells that canonical activation of AhR mediates the activation of the SRC pathway and promotes the acquisition of an invasive and aggressive resistant phenotype to front‐line BRAFi treatment in melanoma. This nongenetic reprogramming identifies a clinically compatible approach to reverse BRAFi resistance in melanoma. Using a preclinical BRAFi‐resistant PDX melanoma model, we demonstrate that SRC inhibition with dasatinib significantly re‐sensitizes melanoma cells to BRAFi. Together we identify the AhR/SRC axis as a new therapeutic vulnerability to trigger resistance and warrant the introduction of SRC inhibitors during the course of the treatment in combination with front‐line therapeutics to delay BRAFi resistance. This study reports that the AhR/SRC axis constitutes a therapeutic vulnerability in BRAFi‐resistant melanoma. This study reports that the AhR/SRC axis constitutes a therapeutic vulnerability in BRAFi‐resistant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SRC activation has been also implicated in innate or acquired resistance to targeted drugs, such as cetuximab in KRAS mutant CRC [32] or BRAFi in BRAFV600E melanoma patients [33, 34]”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“Our hypothesis is also further reinforced by published reports in BRAFV600E melanoma that showed activation of the SRC pathway by Aryl hydrocarbon Receptor (AhR) promotes the acquisition of an invasive and aggressive phenotype resistant to front-line BRAF inhibitors [34].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,037
Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888
Reinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1370 · Cited by 887
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771
In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743
Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639
OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs
Anaya, J. (2016) · PeerJ Computer Science · doi:10.7717/peerj-cs.67 · Cited by 639
The emerging clinical relevance of genomics in cancer medicine
Berger, M. F., & Mardis, E. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0002-6 · Cited by 626
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes & Development · doi:10.1101/gad.406406 · Cited by 608
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 600
Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7683 · Cited by 489
Ligand binding and activation of the Ah receptor
Denison, M. S., Pandini, A., Nagy, S. R., Baldwin, E. P., & Bonati, L. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00063-7 · Cited by 485
Goding, C. R., & Arnheiter, H. (2019) · Genes & Development · doi:10.1101/gad.324657.119 · Cited by 430
RAF inhibitors that evade paradoxical MAPK pathway activation
Zhang, C., Spevak, W., Zhang, Y., Burton, E. A., Ma, Y., Habets, G., Zhang, J., Lin, J., Ewing, T., Matusow, B., et al. (2015) · Nature · doi:10.1038/nature14982 · Cited by 382
Girotti, M. R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0386 · Cited by 382
Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 246
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216
Girotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
Enan, E., & Matsumura, F. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00566-7 · Cited by 197
Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
Wellbrock, C., & Marais, R. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505059 · Cited by 196
Targeted Therapy in Melanoma and Mechanisms of Resistance
Czarnecka, A. M., Bartnik, E., Fiedorowicz, M., & Rutkowski, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134576 · Cited by 196
Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194
Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells
Cheli, Y., Giuliano, S., Fenouille, N., Allegra, M., Hofman, V, Hofman, P., Bahadoran, P., Lacour, J.-P., Tartare-Deckert, S., Bertolotto, C., et al. (2012) · Oncogene · doi:10.1038/onc.2011.425 · Cited by 185
Development of encorafenib for BRAF-mutated advanced melanoma
Koelblinger, P., Thuerigen, O., & Dummer, R. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000426 · Cited by 177
Song, C., Piva, M., Sun, L., Hong, A., Moriceau, G., Kong, X., Zhang, H., Lomeli, S., Qian, J., Yu, C. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0401 · Cited by 158
Patel, A., Sabbineni, H., Clarke, A., & Somanath, P. R. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.05.036 · Cited by 156
A phase 2 trial of dasatinib in advanced melanoma
Kluger, H. M., Dudek, A. Z., McCann, C., Ritacco, J., Southard, N., Jilaveanu, L. B., Molinaro, A., & Sznol, M. (2011) · Cancer · doi:10.1002/cncr.25766 · Cited by 151
Encorafenib and Binimetinib: First Global Approvals
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0963-x · Cited by 149
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O., Rogiers, A., Dewaele, M., Femel, J., Karras, P., Pozniak, J., Bervoets, G., Van Raemdonck, N., Pedri, D., Swings, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.015 · Cited by 141
Self-citationThe aryl hydrocarbon receptor regulates focal adhesion sites through a non-genomic FAK/Src pathway
Tomkiewicz, C., Herry, L., Bui, L.-C., Metayer, C., Bourdeloux, M., Barouki, R., & Coumoul, X. (2012) · Oncogene · doi:10.1038/onc.2012.197 · Cited by 137
Evolving impact of long-term survival results on metastatic melanoma treatment
Michielin, O. A., Atkins, M. B., Koon, H. B., Dummer, R., & Ascierto, P. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000948 · Cited by 125
Overcoming resistance to BRAF inhibitors
Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 123
The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis
Zhang, X., Yang, L., Szeto, P., Abali, G. K., Zhang, Y., Kulkarni, A., Amarasinghe, K. C., Li, J., Vergara, I. A., Molania, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1362-9 · Cited by 119
Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845
Sato, K.-I. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140610761 · Cited by 109
Definition of a Dioxin Receptor Mutant That Is a Constitutive Activator of Transcription
McGuire, J., Okamoto, K., Whitelaw, M. L., Tanaka, H., & Poellinger, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105607200 · Cited by 102
Rossi, A., Roberto, M., Panebianco, M., Botticelli, A., Mazzuca, F., & Marchetti, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172621 · Cited by 99
Cooperation of heat shock protein 90 and p23 in aryl hydrocarbon receptor signaling
Cox, M. B., & Miller, C. A. (2004) · Cell Stress and Chaperones · doi:10.1379/1466-1268(2004)009<0004:cohspa>2.0.co;2 · Cited by 99
Corre, S., Tardif, N., Mouchet, N., Leclair, H. M., Boussemart, L., Gautron, A., Bachelot, L., Perrot, A., Soshilov, A., Rogiers, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06951-2 · Cited by 98
Self-citationPreclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Eustace, A. J., Crown, J., Clynes, M., & O'Donovan, N. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-53 · Cited by 94
Xie, G., Peng, Z., & Raufman, J.-P. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00427.2011 · Cited by 93
Administration of Hsp70 in vivo inhibits motor and sensory neuron degeneration
Tidwell, J. L., Houenou, L. J., & Tytell, M. (2004) · Cell Stress and Chaperones · doi:10.1379/csc-9r.1 · Cited by 89
MITF reprograms the extracellular matrix and focal adhesion in melanoma
Dilshat, R., Fock, V., Kenny, C., Gerritsen, I., Lasseur, R. M. J., Travnickova, J., Eichhoff, O. M., Cerny, P., Möller, K., Sigurbjörnsdóttir, S., et al. (2021) · eLife · doi:10.7554/elife.63093 · Cited by 84
Ye, M., Zhang, Y., Gao, H., Xu, Y., Jing, P., Wu, J., Zhang, X., Xiong, J., Dong, C., Yao, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0396 · Cited by 80
Sato, K., Nagao, T., Iwasaki, T., Nishihira, Y., & Fukami, Y. (2003) · Genes to Cells · doi:10.1046/j.1356-9597.2003.00691.x · Cited by 73
DAUD, A. I., Gill, J., Kamra, S., Chen, L., & Ahuja, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0369-8 · Cited by 66
Vendramin, R., Katopodi, V., Cinque, S., Konnova, A., Knezevic, Z., Adnane, S., Verheyden, Y., Karras, P., Demesmaeker, E., Bosisio, F. M., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210571 · Cited by 61
Self-citationNukaya, M., Lin, B. C., Glover, E., Moran, S. M., Kennedy, G. D., & Bradfield, C. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.132043 · Cited by 60
Trametinib (GSK1120212) in the treatment of melanoma
Salama, A. K. S., & Kim, K. B. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.770475 · Cited by 60
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
Rose, A. A. N., Annis, M. G., Frederick, D. T., Biondini, M., Dong, Z., Kwong, L. N., Chin, L., Keler, T., Hawthorne, T. R., Watson, I. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1192 · Cited by 59
Gross, A., Niemetz-Rahn, A., Nonnenmacher, A., Tucholski, J., Keilholz, U., & Fusi, A. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0318-9 · Cited by 51
Randi, A. S., Sánchez, M., Álvarez, L., Cardozo, J., Pontillo, C. A., & de Pisarev, D. L. K. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.01.003 · Cited by 49
Yang, S. Y. C., Ahmed, S., Satheesh, S. V., & Matthews, J. B. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2022-x · Cited by 49
Notarangelo, T., Sisinni, L., Condelli, V., & Landriscina, M. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0457-z · Cited by 41
Said, A. H., Hu, S., Abutaleb, A., Watkins, T., Cheng, K., Chahdi, A., Kuppusamy, P., Saxena, N. K., Xie, G., & Raufman, J. (2017) · Biochemical Journal · doi:10.1042/bcj20160704 · Cited by 38
CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance
Gautron, A., Bachelot, L., Aubry, M., Leclerc, D., Quéméner, A. M., Corre, S., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013466 · Cited by 37
Self-citationKenessey, I., Kramer, Z., István, L., Cserepes, M., Garay, T., Hegedűs, B., Dobos, J., Tímár, J., & Tóvári, J. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000488 · Cited by 33
Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma
Feddersen, C. R., Schillo, J. L., Varzavand, A., Vaughn, H. R., Wadsworth, L. S., Voigt, A. P., Zhu, E. Y., Jennings, B. M., Mullen, S. A., Bobera, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0244 · Cited by 29
The dioxin receptor controls β1 integrin activation in fibroblasts through a Cbp–Csk–Src pathway
Rey-Barroso, J., Coló, G. P., Alvarez, A. M., Redondo-Muñóz, J., Carvajal-González, J. M., Mulero‐Navarro, S., García-Pardo, A., Teixidó, J., & Fernández‐Salguero, P. M. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.01.010 · Cited by 27
Altered integrin expression patterns shown by microarray in human cutaneous melanoma
Vízkeleti, L., Kiss, T., Koroknai, V., Ecsedi, S., Papp, O., Szász, I., Ádány, R., & Balázs, M. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000322 · Cited by 27
Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness
Ruffini, F., Tentori, L., Dorio, A. S., Arcelli, D., d’Amati, G., D’Atri, S., Graziani, G., & Lacal, P. M. (2013) · Oncology Reports · doi:10.3892/or.2013.2791 · Cited by 26
Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
Simiczyjew, A., Pietraszek‐Gremplewicz, K., Dratkiewicz, E., Podgórska, M., Matkowski, R., Ziętek, M., & Nowak, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01116 · Cited by 26
Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines
Noguchi, K., Dalton, A. C., Howley, B. V., McCall, B. J., Yoshida, A., Diehl, J. A., & Howe, P. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177830 · Cited by 25
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus
Nihal, M., & Wood, G. S. (2016) · Oncotarget · doi:10.18632/oncotarget.10861 · Cited by 22
Krayem, M., Aftimos, P. G., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., et al. (2020) · Cancers · doi:10.3390/cancers12020512 · Cited by 22
Goh, C. J. H., Wong, J. H., El Farran, C., Tan, B. X., Coffill, C. R., Loh, Y.-H., Lane, D., & Arumugam, P. (2021) · G3 Genes|Genomes|Genetics · doi:10.1093/g3journal/jkaa069 · Cited by 20
A novel anti-melanoma SRC-family kinase inhibitor
Halaban, R., Bacchiocchi, A., Straub, R., Cao, J. P., Sznol, M., Narayan, D., Allam, A., Krauthammer, M. O., & Mansour, T. S. (2019) · Oncotarget · doi:10.18632/oncotarget.26787 · Cited by 15
Src inhibition induces melanogenesis in human G361 cells
Ku, K.-E., Choi, N., Oh, S. H., Kim, W., Suh, W., & Sung, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9958 · Cited by 8
Close, D. A., Kirkwood, J. M., Fecek, R. J., Storkus, W. J., & Johnston, P. A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220970917 · Cited by 8
Cited by
Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway
Sondermann, N. C., Faßbender, S., Hartung, F., Hätälä, A. M., Rolfes, K. M., Vogel, C. F. A., & Haarmann-Stemmann, T. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115371 · Cited by 181
The complex biology of aryl hydrocarbon receptor activation in cancer and beyond
Opitz, C. A., Holfelder, P., Prentzell, M. T., & Trump, S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115798 · Cited by 120
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation
Polonio, C. M., McHale, K. A., Sherr, D. H., Rubenstein, D., & Quintana, F. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01172-x · Cited by 116
“In particular, AHR inhibitors should target the AHR in malignant cells, where it controls invasiveness, stemness and immunosuppressive genes 250,257,305,306 , and also target the AHR in immune cells, where it promotes immunosuppressive phenotypes 255,307,308 .”
The aryl hydrocarbon receptor: structure, signaling, physiology and pathology
Coumoul, X., Barouki, R., Esser, C., Haarmann‐Stemmann, T., Lawrence, B. P., Lehmann, J., Moura‐Alves, P., Murray, I. A., Opitz, C. A., Perdew, G. H., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02500-8 · Cited by 122
Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling
Slominski, R. M., Kim, T., Janjetović, Z., Brożyna, A. A., Podgórska, E., Dixon, K. M., Mason, R. S., Tuckey, R. C., Sharma, R., Crossman, D. K., et al. (2024) · Cancers · doi:10.3390/cancers16122262 · Cited by 86
Metadata
- Authors
- Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- VIB-KU Leuven Center for Cancer Biology (BE)
- Corresponding author
- Galibert, Marie‐Dominique
- Corre, Sébastien
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2022-10-28
- Volume
- 14
- Issue
- 12
- Pages
- e15677-e15677
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC9728058
- OpenAlex
- W4307492590
- Cited by
- 26
- References
- 87
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 4
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Association Recherche Contre le Cancer (PGA1*20160203868)
- Centre National de la Recherche Scientifique
- FHU CAMIn‐CHU RENNES
- Institut National de la Santé et de la Recherche Médicale
- Institut National Du Cancer (ENV201308, ENV201603)
- Ligue Contre le Cancer
- Stichting Tegen Kanker (2016‐054)
- Université de Rennes 1
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- aryl hydrocarbon receptor, BRAF inhibitor resistance, melanoma, dasatinib, therapeutic vulnerabilities, transcriptional reprogramming, patient-derived xenografts
- MeSH terms
- Dasatinib, Humans, Melanoma, Phenotype, Receptors, Aryl Hydrocarbon, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.